Clearmind kicks off patient enrollment at Tel Aviv Sourasky Medical Center

Clearmind Medicine (CMND) announced that Tel Aviv Sourasky Medical Center has officially kicked off patient enrollment by successfully recruiting the first participant for Clearmind’s FDA-approved multinational Phase I/IIa clinical trial of CMND-100 in Alcohol Use Disorder. The recruitment of the first patient at TASMC, under the leadership of Principal Investigator Prof. David Zeltser, Director of Internal Medicine Department and Deputy Director, R&D and Innovation, marks full activation of this prestigious Israeli site. TASMC now joins an expanding network of world-class centers actively screening and enrolling patients, including Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center.